Procarbazine
As of the edition of 20 October 2026, Procarbazine is a small molecule: marketed, first approved in 1965 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Matulane
- First approved
- 1 December 1965 (ES)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- LEADIANT BIOSCIENCES IRELAND (IRLANDE); 3 holders in all
- Registered trials
- 60, 6 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Nervous system; Chemically induced; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 0 | 0 |
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 33 | 22 | 1 | 4 |
| Phase 3 | 18 | 12 | 4 | 1 |
| All trials | 60 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Leadiant Biosciences | Applicant | 1970 to now |
| Roche | Applicant |